[go: up one dir, main page]

CN108727335A - A kind of purification method of bepotastine besilate - Google Patents

A kind of purification method of bepotastine besilate Download PDF

Info

Publication number
CN108727335A
CN108727335A CN201810891851.8A CN201810891851A CN108727335A CN 108727335 A CN108727335 A CN 108727335A CN 201810891851 A CN201810891851 A CN 201810891851A CN 108727335 A CN108727335 A CN 108727335A
Authority
CN
China
Prior art keywords
bepotastine
benzene sulphur
sulphur bepotastine
purification process
silica gel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810891851.8A
Other languages
Chinese (zh)
Inventor
陈忠
赵学清
邹昕
林燕琴
范琳
成佳威
魏宗有
王娟
郑向阳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujian Institute of Microbiology
Original Assignee
Fujian Institute of Microbiology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Institute of Microbiology filed Critical Fujian Institute of Microbiology
Priority to CN201810891851.8A priority Critical patent/CN108727335A/en
Publication of CN108727335A publication Critical patent/CN108727335A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The invention discloses a purification method of bepotastine besilate, which belongs to the technical field of drug separation and purification, and particularly adopts β -cyclodextrin bonded silica gel as an adsorbent, column chromatography silica gel is used for adsorbing impurities in a crude product of bepotastine besilate, and β -cyclodextrin is used for separating isomers, so that purified bepotastine is obtained.

Description

一种苯磺贝他斯汀的纯化方法A kind of purification method of bepotastine besilate

技术领域technical field

本发明属于药物分离纯化技术领域,具体涉及一种苯磺贝他斯汀的纯化方法。The invention belongs to the technical field of separation and purification of medicines, and in particular relates to a purification method of bepotastine besilate.

背景技术Background technique

苯磺贝他斯汀(Bepotastine Beslilate),化学名为:4-[4-[(S)-[(4-氯苯基)吡啶-2-基]甲氧基]哌啶-1-基]丁酸单苯磺酸盐,分子量为547.06,CAS号为:190786-44-8,其结构式如下:Bepotastine Beslilate, chemical name: 4-[4-[(S)-[(4-chlorophenyl)pyridin-2-yl]methoxy]piperidin-1-yl] Butyric acid monobenzenesulfonate, the molecular weight is 547.06, the CAS number is: 190786-44-8, and its structural formula is as follows:

.

苯磺贝他斯汀是日本田边(Tanabe Seiyaku)公司和日本宇部(Ube Industries)公司联合开发的组胺H-1受体拮抗剂,其对组胺H1受体有高度选择性。还有研究发现,苯磺贝他斯汀能抑制嗜酸粒细胞浸润至外周组织,因此能缓解鼻粘膜的炎症反应。另外,苯磺贝他斯汀很少进入脑内,无镇静作用,抗胆碱作用与抗组胺作用相分离,其它不良反应极小,具有优良的药效学作用和临床效果,作用强度优于酮替芬、特非那定、西替立嗪、依匹那丁,因此临床应用前景广阔。Bepotastine bepotastine is a histamine H-1 receptor antagonist jointly developed by Japan's Tanabe Seiyaku and Japan's Ube Industries, which is highly selective for histamine H1 receptors. Other studies have found that bepotastine bepotastine can inhibit the infiltration of eosinophils into peripheral tissues, thereby alleviating the inflammatory response of the nasal mucosa. In addition, bepotastine besilate rarely enters the brain, has no sedative effect, the anticholinergic effect is separated from the antihistamine effect, and other adverse reactions are minimal. In ketotifen, terfenadine, cetirizine, epinadine, so the prospect of clinical application is broad.

现有研究显示,苯磺贝他斯汀不同异构体在药理作用上的显著差异,其中S异构体比R异构体药理作用强100倍以上,且S异构体血浆蛋白结合率比R型高,故作为杂质的苯磺贝他斯汀中R异构体的含量越少越好。现有文献中没有专门关于苯磺贝他斯汀纯化的报道,常采用重结晶法进行纯化。重结晶法虽然可以得到纯度95%的苯磺贝他斯汀,但是要进一步纯化得到纯度99.5%以上的苯磺贝他斯汀,同时使光学异构体控制在检测限以下,现有纯化方法还无法实现。因此急需提出新的方案对苯磺贝他斯汀进行有效纯化。Existing studies have shown that there are significant differences in the pharmacological effects of different isomers of bepotastine besilate, among which the pharmacological effect of the S isomer is more than 100 times stronger than that of the R isomer, and the plasma protein binding rate of the S isomer is higher than that of the R isomer. The R type is high, so the less the R isomer content in bepotastine bepotastine as an impurity, the better. There is no special report on the purification of bepotastine besilate in the existing literature, and recrystallization is often used for purification. Although the recrystallization method can obtain bepotastine bepotastine with a purity of 95%, it needs to be further purified to obtain bepotastine with a purity of more than 99.5%, while keeping the optical isomers below the detection limit. Not yet possible. Therefore, it is urgent to propose a new scheme to effectively purify bepotastine besilate.

发明内容Contents of the invention

本发明针对现有技术存在的问题,提供了一种可有效提高苯磺贝他斯汀纯度,且可操作性好、适合于大规模工业化生产的纯化方法。Aiming at the problems existing in the prior art, the present invention provides a purification method that can effectively improve the purity of bepotastine besilate, has good operability and is suitable for large-scale industrial production.

为实现上述目的,本发明采用如下技术方案:To achieve the above object, the present invention adopts the following technical solutions:

一种苯磺贝他斯汀的纯化方法,其包括以下步骤:A purification method of bepotastine besilate, which comprises the following steps:

1)将苯磺贝他斯汀粗品溶解于有机溶剂中,形成苯磺贝他斯汀溶液;1) Dissolving the crude product of bepotastine besilate in an organic solvent to form a bepotastine besilate solution;

2)将β-环糊精键合硅胶用有机溶剂溶散,形成键合硅胶溶液;2) Dissolve β-cyclodextrin bonded silica gel with an organic solvent to form a bonded silica gel solution;

3)在搅拌条件下将苯磺贝他斯汀溶液滴入键合硅胶溶液中,过滤、水洗后取有机层浓缩至干,得到纯化的苯磺贝他斯汀。3) Drop the bepotastine bepotastine solution into the bonded silica gel solution under stirring conditions, filter and wash with water, then take the organic layer and concentrate to dryness to obtain purified bepotastine bepotastine.

所述苯磺贝他斯汀粗品的纯度为95%-98%,光学纯度为0.5%-1%。The purity of the crude bepotastine besilate is 95%-98%, and the optical purity is 0.5%-1%.

所用β-环糊精键合硅胶与苯磺贝他斯汀粗品的重量比为3-4:1,以保证充分去除杂质,并避免β-环糊精键合硅胶用量过大而导致的溶剂用量的增加以及收率的降低。The weight ratio of the β-cyclodextrin-bonded silica gel to the crude product of bepotastine besilate is 3-4:1 to ensure sufficient removal of impurities and to avoid solvent contamination caused by excessive use of β-cyclodextrin-bonded silica gel. An increase in dosage and a decrease in yield.

有机溶剂加入量过多可能导致杂质不能吸附完全,加入量过少可能导致收率降低,因此,操作中所用有机溶剂与苯磺贝他斯汀粗品的重量比为5-20:1;其中,所述有机溶剂为正丁醇、乙酸乙酯、二氯甲烷中的一种或几种,优选乙酸乙酯。Too much addition of organic solvent may cause impurities to be unable to absorb completely, and too little addition may cause yield reduction. Therefore, the weight ratio of organic solvent used in the operation to the crude product of bepotastine besilbestatin is 5-20:1; wherein, The organic solvent is one or more of n-butanol, ethyl acetate and dichloromethane, preferably ethyl acetate.

步骤3)中滴加的时间控制在1-2小时。The time of dropping in step 3) is controlled within 1-2 hours.

步骤3)采用过滤除去吸附杂质的固形物时,滤饼可用乙酸乙酯清洗,以使滤饼中的苯磺贝他斯汀洗出;清洗时优选0-5℃的乙酸乙酯,其可有效洗出苯磺贝他斯汀而不洗脱杂质,达到较佳的分离效果。Step 3) When filtration is used to remove the solid matter of adsorbed impurities, the filter cake can be washed with ethyl acetate to wash out the bepotastine besil in the filter cake; ethyl acetate at 0-5°C is preferred for cleaning, which can Effectively wash out bepotastine besilate without eluting impurities, achieving better separation effect.

步骤3)中所述水洗是在滤液中加入其体积0.2-0.3倍的水清洗两次,以除去有机相中可能混有的β-环糊精等杂质。The water washing in step 3) is to add 0.2-0.3 times the volume of water to the filtrate to wash twice, so as to remove impurities such as β-cyclodextrin that may be mixed in the organic phase.

经上述步骤纯化后,所得苯磺贝他斯汀的纯度可达99.5%,其还可经重结晶进一步纯化,其具体步骤为:将所得纯化的苯磺贝他斯汀于溶剂中加热溶解,然后将其降温至0-20℃,使其析出固体,再经过滤、干燥得到高纯度苯磺贝他斯汀。After purification through the above steps, the purity of bepotastine bepotastine obtained can reach 99.5%, and it can be further purified by recrystallization. The specific steps are: heating and dissolving the obtained purified bepotastine in a solvent, Then lower the temperature to 0-20°C to precipitate solids, and then filter and dry to obtain high-purity bepotastine besilate.

所述溶剂与纯化的的苯磺贝他斯汀的重量比为5-20:1;其中,所述溶剂为丙酮、乙酸乙酯、乙酸丙酯、甲醇、乙醇、异丙醇、正己烷、正庚烷中的一种或几种。The weight ratio of the solvent to the purified bepotastine bepotastine is 5-20:1; wherein the solvent is acetone, ethyl acetate, propyl acetate, methanol, ethanol, isopropanol, n-hexane, One or more of n-heptane.

本发明的显著优点在于:Significant advantage of the present invention is:

(1)本发明中将苯磺贝他斯汀粗品溶解于有机溶剂,再用β-环糊精键合硅胶对溶液中的绝大部分杂质进行有效吸附,而不影响目标物苯磺贝他斯汀,再采用过滤和浓缩的方法得到纯度99.5%以上的苯磺贝他斯汀。经进一步重结晶纯化后,能够有效去除苯磺贝他斯汀粗品中的杂质和异构体,所得高纯度苯磺贝他斯汀的纯度可达99.9%,R异构体杂质低于检测限。(1) In the present invention, the crude product of bepotastine besilate is dissolved in an organic solvent, and then β-cyclodextrin-bonded silica gel is used to effectively adsorb most of the impurities in the solution without affecting the target product bepotastine Bepotastine bepotastine with a purity of more than 99.5% is obtained by filtering and concentrating. After further recrystallization and purification, the impurities and isomers in the crude product of bepotastine besylate can be effectively removed, and the purity of the obtained high-purity bepotastine besylate can reach 99.9%, and the R isomer impurity is lower than the detection limit .

(2)本发明无需采用操作难度大、不适合工业化生产的硅胶柱层析方法进行纯化,仅利用β-环糊精键合硅胶吸附以及重结晶方法进行纯化,其纯化过程操作简便,操作时间短,对操作人员要求不高,并省去了大量有机溶剂的使用,且产品收率高,纯度高,异构体也降到检测限附近,适用于高纯度苯磺贝他斯汀规模化工业生产。(2) The present invention does not need to adopt the silica gel column chromatography method which is difficult to operate and is not suitable for industrial production for purification, but only uses β-cyclodextrin-bonded silica gel adsorption and recrystallization methods for purification. The purification process is easy to operate and takes less time to operate. Short, low requirements for operators, and save the use of a large number of organic solvents, and the product yield is high, high purity, isomers are also reduced to near the detection limit, suitable for large-scale production of high-purity bepotastine besilate industrial production.

具体实施方式Detailed ways

为了使本发明所述的内容更加便于理解,下面结合具体实施方式对本发明所述的技术方案做进一步的说明,但是本发明不仅限于此。In order to make the content of the present invention easier to understand, the technical solutions of the present invention will be further described below in conjunction with specific embodiments, but the present invention is not limited thereto.

在50L反应釜中,加入无水二甲基甲酰胺30L和0.5kg干燥过的β-环糊精,并加入2.5g金属钠,搅拌混合;称取5kg柱层析用硅胶、0.05kg经干燥过的3-缩水甘油基氧丙基三甲氧基硅烷,加入反应釜中,搅拌混合;升温至105℃,反应12小时,过滤,滤饼用无水二甲基甲酰胺、丙酮、水各洗三次,60℃条件下减压干燥5小时,得到β-环糊精键合硅胶。In a 50L reaction kettle, add 30L of anhydrous dimethylformamide and 0.5kg of dried β-cyclodextrin, and add 2.5g of sodium metal, stir and mix; weigh 5kg of silica gel for column chromatography, 0.05kg of dried Add the 3-glycidyloxypropyltrimethoxysilane to the reaction kettle, stir and mix; raise the temperature to 105°C, react for 12 hours, filter, and wash the filter cake with anhydrous dimethylformamide, acetone, and water Three times, drying under reduced pressure at 60° C. for 5 hours to obtain β-cyclodextrin-bonded silica gel.

其中,所用柱层析硅胶为100-300目,优选200-300目,较细硅胶具有较好的杂质吸附效果,而且分离和过滤较容易。Wherein, the column chromatography silica gel used is 100-300 mesh, preferably 200-300 mesh, and finer silica gel has better impurity adsorption effect, and is easier to separate and filter.

1. β-环糊精键合硅胶吸附纯化苯磺贝他斯汀粗品1. Purification of crude bepotastine besilate by adsorption on β-cyclodextrin bonded silica gel

将乙酸乙酯和苯磺贝他斯汀粗品加入玻璃瓶中,搅拌溶解后得到苯磺贝他斯汀溶液,备用;将β-环糊精键合硅胶和乙酸乙酯投入反应釜中,搅拌溶散后得到键合硅胶溶液;在搅拌条件下将苯磺贝他斯汀溶液滴入键合硅胶溶液中,滴加时间1-2小时;然后过滤,滤饼用乙酸乙酯清洗后合并滤液和洗液,加入其体积0.2-0.3倍的水洗两次,取乙酸乙酯层浓缩至干,得到苯磺贝他斯汀。Add ethyl acetate and crude bepotastine bepotastine into a glass bottle, stir and dissolve to obtain a solution of bepotastine besilate for later use; put β-cyclodextrin bonded silica gel and ethyl acetate into the reaction kettle, stir After dissolving, a bonded silica gel solution is obtained; drip bepotastine bepotastine solution into the bonded silica gel solution under stirring conditions, and the dropping time is 1-2 hours; then filter, the filter cake is washed with ethyl acetate and the filtrate is combined and washing solution, add 0.2-0.3 times the volume of water to wash twice, take the ethyl acetate layer and concentrate to dryness to obtain bepotastine besilate.

上述操作中,苯磺贝他斯汀粗品投料量、纯度、反应釜容积、溶剂用量、β-环糊精键合硅胶用量及经β-环糊精键合硅胶吸附纯化后得到的苯磺贝他斯汀的纯化结果如表1实施例1-5所示。In the above operation, the amount of crude product of bepotastine bepotastine, purity, reaction kettle volume, solvent usage, dosage of β-cyclodextrin bonded silica gel and the amount of bepotastine obtained after adsorption and purification of β-cyclodextrin bonded silica gel The purification results of stastatin are shown in Table 1, Examples 1-5.

表1 β-环糊精键合硅胶吸附纯化苯磺贝他斯汀粗品的参数及结果Table 1 Parameters and results of purification of crude bepotastine besilate by adsorption on β-cyclodextrin bonded silica gel

由表1可见,纯度95.1%-97.6%、异构体含量0.82%-0.99%的苯磺贝他斯汀粗品经过β-环糊精键合硅胶纯化后,苯磺贝他斯汀纯度得到大幅提升,纯度均达到99.5%以上,同时异构体含量也降到0.3%以下,符合苯磺贝他斯汀原料药质量标准的基本要求。It can be seen from Table 1 that after the crude product of bepotastine bepotastine with a purity of 95.1%-97.6% and an isomer content of 0.82%-0.99% was purified by β-cyclodextrin-bonded silica gel, the purity of bepotastine besilate was greatly improved. Improvement, the purity reaches more than 99.5%, and the isomer content is also reduced to less than 0.3%, which meets the basic requirements of the quality standard of bepotastine besilate raw material.

2. 重结晶纯化苯磺贝他斯汀2. Purification of bepotastine besilate by recrystallization

将上述制得的苯磺贝他斯汀用有机溶剂加热回流溶解,降温至T℃析出固体,过滤、干燥得到高纯度苯磺贝他斯汀,其纯化效果见表2。The bepotastine bepotastine prepared above was dissolved in an organic solvent under reflux, cooled to T°C to precipitate a solid, filtered, and dried to obtain high-purity bepotastine bepotastine. The purification effect is shown in Table 2.

表2苯磺贝他斯汀进一步纯化的参数及结果Table 2 Parameters and results of further purification of bepotastine besilate

由表2可见,所得苯磺贝达他斯汀经进一步重结晶纯化后,所得成品的纯度均达到99.9%以上,成品中异构体均为未检出(低于最低检出限)。It can be seen from Table 2 that after further recrystallization and purification of the obtained bedastatin besylate, the purity of the obtained finished products all reached above 99.9%, and no isomers were detected in the finished products (below the minimum detection limit).

以上所述仅为本发明的较佳实施例,凡依本发明申请专利范围所做的均等变化与修饰,皆应属本发明的涵盖范围。The above descriptions are only preferred embodiments of the present invention, and all equivalent changes and modifications made according to the scope of the patent application of the present invention shall fall within the scope of the present invention.

Claims (8)

1. a kind of purification process of benzene sulphur bepotastine, it is characterised in that:Include the following steps:
1)Benzene sulphur bepotastine crude product is dissolved in organic solvent, benzene sulphur bepotastine solution is formed;
2)Beta-cyclodextrin bonded silica gel is leached with organic solvent, forms bonded silica gel solution;
3)Benzene sulphur bepotastine solution is instilled in bonded silica gel solution under agitation, takes organic layer dense after filtering, washing It is reduced to dry, to be purified benzene sulphur bepotastine.
2. the purification process of benzene sulphur bepotastine according to claim 1, it is characterised in that:The benzene sulphur bepotastine crude product Purity be 95%-98%.
3. the purification process of benzene sulphur bepotastine according to claim 1, it is characterised in that:Beta-cyclodextrin bonded silica gel used Weight ratio with benzene sulphur bepotastine crude product is 3-4:1.
4. the purification process of benzene sulphur bepotastine according to claim 1, it is characterised in that:Organic solvent used is total in operation Amount and the weight ratio of benzene sulphur bepotastine crude product are 5-20:1;
Wherein, the organic solvent is one or more of n-butanol, ethyl acetate, dichloromethane.
5. the purification process of benzene sulphur bepotastine according to claim 1, it is characterised in that:Step 3)The time of middle dropwise addition is controlled System was at 1-2 hours.
6. the purification process of benzene sulphur bepotastine according to claim 1, it is characterised in that:Step 3)Described in washing be The water cleaning of 0.2-0.3 times of its volume is added in filtrate twice.
7. the purification process of benzene sulphur bepotastine according to claim 1, it is characterised in that:The benzene sulphur Beta that gained is purified Sting dissolves by heating in solvent, is then cooled to 0-20 DEG C, makes it that solid be precipitated, high-purity using filtering, being dried to obtain Spend benzene sulphur bepotastine.
8. benzene sulphur bepotastine purification process according to claim 7, it is characterised in that:The benzene of the solvent and purifying The weight ratio of sulphur bepotastine is 5-20:1;
Wherein, the solvent is in acetone, ethyl acetate, propyl acetate, methanol, ethyl alcohol, isopropanol, n-hexane, normal heptane It is one or more of.
CN201810891851.8A 2018-08-07 2018-08-07 A kind of purification method of bepotastine besilate Pending CN108727335A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810891851.8A CN108727335A (en) 2018-08-07 2018-08-07 A kind of purification method of bepotastine besilate

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810891851.8A CN108727335A (en) 2018-08-07 2018-08-07 A kind of purification method of bepotastine besilate

Publications (1)

Publication Number Publication Date
CN108727335A true CN108727335A (en) 2018-11-02

Family

ID=63942374

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810891851.8A Pending CN108727335A (en) 2018-08-07 2018-08-07 A kind of purification method of bepotastine besilate

Country Status (1)

Country Link
CN (1) CN108727335A (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1242013A (en) * 1996-12-26 2000-01-19 宇部兴产株式会社 Acid addition salts of optically active piperidine compounds and process for preparing the same
US20140046068A1 (en) * 2012-08-10 2014-02-13 Everlight Usa, Inc. Method of synthesizing bepotastine or benzenesulfonic acid salt thereof and intermediates used therein
CN106117183A (en) * 2016-06-24 2016-11-16 合肥久诺医药科技有限公司 A kind of process for purification of high-purity benzene sulphur bepotastine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1242013A (en) * 1996-12-26 2000-01-19 宇部兴产株式会社 Acid addition salts of optically active piperidine compounds and process for preparing the same
US20140046068A1 (en) * 2012-08-10 2014-02-13 Everlight Usa, Inc. Method of synthesizing bepotastine or benzenesulfonic acid salt thereof and intermediates used therein
CN106117183A (en) * 2016-06-24 2016-11-16 合肥久诺医药科技有限公司 A kind of process for purification of high-purity benzene sulphur bepotastine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
夏俊等: "苯磺酸贝他斯汀的合成新方法", 《中国医药工业杂志》 *
白熙等: "不同交联剂对羟乙基β-环糊精固定相选择性的影响", 《长治医学院学报》 *

Similar Documents

Publication Publication Date Title
CN105440040B (en) The purification process of Buddhist nun is replaced according to Shandong
CN105085373B (en) Purification method of apremilast product
CN113292533A (en) Method for purifying polymer impurities in lipoic acid
CN106256824B (en) Preparation method of high-purity delafloxacin meglumine salt
CN105418581A (en) Preparation method of trelagliptin succinate
CN110655511B (en) Preparation and refining method of high-purity empagliflozin
CN102351847B (en) Industrial method for refining esomeprazole sodium salt
CN102775387B (en) Method for refining fasudil hydrochloride
WO2020207130A1 (en) Process for separating and purifying artemisinin
CN105481856A (en) Preparation method of palipefidone
CN103044323B (en) A kind of purification process of SASP
CN108727335A (en) A kind of purification method of bepotastine besilate
CN106543025A (en) A kind of preparation method of high-purity hydrochloric acid doxycycline
CN103613579A (en) Bilastine purifying method
WO2022142385A1 (en) Method for refining dienogest
CN101560188B (en) Method for separating and purifying 2-methylimidazole crystal impurity
CN108976224B (en) Method for extracting and purifying ergometrine from fermentation liquor
CN116396146B (en) A continuous crystallization method for cannabidiol
CN103588841B (en) The process for purification of trihydroxy-oestrin
CN111153862B (en) A kind of refining method of Recinade
WO2023138341A1 (en) Synthesis method for ertapenem sodium
CN110606844B (en) Mupirocin purification method
CN102391094A (en) Crystallization method for preparing high-purity idebenone
CN104892501A (en) Aftertreatment purification method for 3-[(3-amino-4-methylamino benzoyl)(pyridine-2-yl)amino]ethyl propionate
CN116396346B (en) A method for reducing free fatty acids in dexamethasone palmitate

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181102

RJ01 Rejection of invention patent application after publication